Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02434692
Other study ID # ARGOS-02
Secondary ID CIV-13-11-011719
Status Completed
Phase N/A
First received September 2, 2014
Last updated August 16, 2017
Start date May 2014
Est. completion date April 11, 2017

Study information

Verified date August 2017
Source Implandata Ophthalmic Products GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients with POAG and indicated cataract surgery.


Description:

This prospective, open-label, multi center, single-arm clinical investigation will enroll 22 consecutive patients.

Enrollment will be temporarily halted in case a serious adverse device effect (SADE) occurs, and Data and Safety Monitoring Board (DSMB) meeting will be conducted as soon as possible. The DSMB will then recommend whether to further continue the study as planned, or whether enrollment shall be stopped. In order to provide a complete overview of the study to the DSMB, an interim analysis will be performed after half of the study population (11-14 subjects) is enrolled with a minimum follow-up of 1 month. A conclusion for safety will be made if in total no more than 2 of the total of 22 patients experience a SADE.

The primary aim of this study is to show "safety", which will be evaluated based on the percentage of subjects who experience a SADE (="non-safety"), as defined in the primary endpoints.

The study will be declared a success if the final non-safety event rate is less than 6% (type II error rate of 0.20). The calculation is based on a design optimizing the minimum expected sample size with parameters alpha=0.05, beta=0.20, p0=0.75, p1=0.94.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date April 11, 2017
Est. primary completion date April 11, 2017
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria:

1. Mentally competent and willing to provide written informed consent

2. Male or female aged =40 and =85 years. Female subjects of childbearing potential must be willing to use adequate contraception and must have a negative pregnancy test.

3. Diagnosis of primary open-angle glaucoma (POAG) including high pressure glaucoma (HPG), normal pressure glaucoma (NPG) and ocular hypertension (OH), as defined by the European Glaucoma Society guideline (Heijl, Treverso, et al., 2008)

4. Sufficiently controlled intraocular pressure (IOP)

5. Study eye needs to be phakic

6. Only one eye per patient may be implanted with the ARGOS-IO implant

7. Cataract surgery indicated. The medical indication for a cataract operation must be given irrespective of the study participation. Potential study patients will be solicited for participation in the clinical trial only after the patient has given consent to the cataract operation.

8. Pre-operative anterior chamber depth (ACD) =2.0 mm as measured from the corneal endothelium

9. Axis length >22 mm

10. Endothelial cell density of the cornea =2000 cells/mm²

11. Subjects able and willing to attend all scheduled visits and comply with all study procedures

Exclusion Criteria:

1. Any other type of glaucoma other than primary open-angle glaucoma as defined by inclusion criterion 3

2. Severe POAG patients with a macular degeneration and visual field loss of -20 decibels (dB) or worse in both eyes. In case of a diverse developed visual field loss, the sensor can be implanted in the worse eye for protection the better eye.

3. Exudative age-related macular degeneration, instable macular degeneration 30 days prior to inclusion, or macular edema

4. Retinal detachment

5. Corneal diseases, especially diseases affecting the corneal endothelium, e.g. Fuchs' Dystrophia

6. Diabetes mellitus

7. Existence of Marfan-Syndrome, Ehlers-Danlos-Syndrome or Weill-Marchesani-Syndrome

8. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to ARGOS-IO implantation

9. Intraocular surgical procedure(s) within 6 months prior to ARGOS-IO implantation or any surgical procedure such as refractive eye surgery in the study eye that can affect the assessment of IOP by Goldmann applanation tonometry

10. History of eye tumor

11. Ocular disease other than glaucoma that may affect assessment of visual acuity and/or IOP by Goldmann applanation tonometry (choroidal hemorrhage or detachment, lens subluxation, thyroid ophthalmopathy)

12. Anterior chamber configuration that puts the subject at high risk to develop an angle closure glaucoma

13. History of extensive keloid formation

14. Severe dry eye syndrome

15. Subjects who will need to undergo ancillary procedures in the study eye at the time of implantation or during the post-operative study period

16. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, plaster or silicone (component of the device)

17. Existence of other active medical eye implant and/or other active medical implants in the head/neck region

18. Any contraindication for intraocular lens (IOL) implantation such as choroidal hemorrhage, concomitant severe eye disease, excessive vitreous loss, extremely shallow anterior chamber, microphthalmos, non-age-related cataract, posterior capsular rupture, severe corneal dystrophy, untraceable IOP, zonular separation, color vision deficiencies

19. Severe generalized disease resulting in a life expectancy shorter than a year

20. Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device

21. Currently pregnant or breastfeeding

22. Participation in any study involving an investigational drug or device within the past 30 days or ongoing participation in a study with an investigational drug or device

23. Patients who are not suitable for the study based on the surgeon's evaluation

24. Patients unable or unwilling to understand or comply with required study procedures

25. Patients with psychiatric disorders influencing their judgement or autonomy

26. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this study, the sponsor or the contract research organization.

27. Enrollment of the fellow eye in this clinical study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ARGOS-IO system
Implantation of ARGOS-IO pressure sensor after cataract surgery on day 0 (V01)

Locations

Country Name City State
Germany Augenklinik Universitätsklinikum Aachen Aachen
Germany Augen-Zentrum-Nordwest Ahaus
Germany Universitäts-Augenklinik Bochum Bochum
Germany Internationale Innovative Ophthalmochirurgie Breyer-Kaymak-Klabe Düsseldorf
Germany Augenklinik der SLK-Kliniken Heilbronn
Germany nordBLICK Augenklinik Bellevue Kiel
Germany Universitätsaugenklinik Magdeburg Magdeburg
Germany Augenärztliches Augenchirurgisches Zentrum (AAZ) Nürnberg
Germany Klinik und Poliklinik für Augenheilkunde der Universität Rostock Rostock
Germany Knappschaftsklinikum Saar - Augenklinik Sulzbach
Germany Universitäts-Augenklinik Tübingen

Sponsors (1)

Lead Sponsor Collaborator
Implandata Ophthalmic Products GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Number of patients experiencing a device related serious adverse event (SAE) defined as any adverse event that both
Is considered by the Investigator to have a possible, probable or definite relationship to the device and
That meets any of the following criteria of a serious adverse event:
Resulted in death, permanent damage or disability or a congenital anomaly
Was life threatening
Required hospitalization or intervention to prevent permanent impairment or damage
12 months
Secondary Incidence of adverse events Incidence of observed adverse events and adverse device events during a period between 3 months and 12 months following implantation. 12 months
Secondary Severity of adverse events Severity of observed adverse events and adverse device events during a period between 3 months and 12 months following implantation. 12 months
Secondary Performance Limits of agreement between measurements made using GAT and the ARGOS-IO system from V05 (day 30) through V11 (day 360) 12 months
See also
  Status Clinical Trial Phase
Completed NCT01085357 - Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery N/A
Completed NCT02700984 - A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial N/A
Recruiting NCT06016972 - Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients Phase 2
Completed NCT01517477 - One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects N/A
Terminated NCT01180062 - Safety Study of Latanoprost Slow Release Insert Phase 1
Terminated NCT03478293 - iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications N/A
Completed NCT01166659 - Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy N/A
Completed NCT01252849 - Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects N/A
Active, not recruiting NCT00902109 - Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients N/A